Cytokine Storm Clinical Trial
Official title:
Clinical Study on the Treatment of Pediatric Hemophagocytic Lymphohistiocytosis Based on Cytokine Guided Risk Stratification:A Multicenter Randomized Controlled Study
Hemophagocytic lymphohistiocytosis (HLH) is a rapidly fatal disease caused by immune-dysregulation characterized by hypercytokinemia, with about 30%-40% of patients suffering death in children. Stratification strategy and individualized treatment is important to improve the survival. In our recent retrospective study, risk stratification based on IL-10 and IFN-γ levels well distinguished patients with different outcomes. In this multicenter prospective study, we will enroll the newly diagnosed pediatric HLH patients and divide them into low, intermediate and high-risk cytokine groups according to IFN-γ and IL-10 levels. The patients'clinical manifestation and laboratory findings will be further evaluated into severe and non-severe groups. For low/intermediate risk and non-severe patients, steroid or ruxolitinib will be used initially; while those with high risk or severe diseases, DXM+VP16±ruxolitinib will be administered. The treatment strategy could be adjusted after evaluation 48-72 hours later.
Status | Recruiting |
Enrollment | 400 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Day to 18 Years |
Eligibility | Inclusion Criteria: - Age from one day to 18 years old; - Newly diagnosed HLH, fulfilling the HLH criteria; - To observed the early diagnosis role of cytokines, patients who is suspected to be HLH and fulfill 3 out of 8 criteria can be pre-enrolled. Exclusion Criteria: - treated with steroids or etoposide within 72 hours before diagnosis. |
Country | Name | City | State |
---|---|---|---|
China | The Children's Hospital of Zhejiang University School of Medicine | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
The Children's Hospital of Zhejiang University School of Medicine | Children's Hospital of Fudan University, Children's Hospital of Nanjing Medical University, Children's Hospital Of Soochow University, First Affiliated Hospital, Sun Yat-Sen University, Hunan Provincial People's Hospital, Institute of Hematology & Blood Diseases Hospital, Qilu Hospital of Shandong University, Second Affiliated Hospital of Wenzhou Medical University, Shanghai Children's Hospital, Shanghai Children's Medical Center, Shenzhen Children's Hospital, The Affiliated Hospital of Qingdao University, The Second Hospital of Anhui Medical University, The Third Xiangya Hospital of Central South University, Tongji Hospital, Union hospital of Fujian Medical University, West China Second University Hospital, Wuhan Children's Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Zunyi Medical College |
China,
Bergsten E, Horne A, Aricó M, Astigarraga I, Egeler RM, Filipovich AH, Ishii E, Janka G, Ladisch S, Lehmberg K, McClain KL, Minkov M, Montgomery S, Nanduri V, Rosso D, Henter JI. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017 Dec 21;130(25):2728-2738. doi: 10.1182/blood-2017-06-788349. Epub 2017 Sep 21. — View Citation
Ehl S, Astigarraga I, von Bahr Greenwood T, Hines M, Horne A, Ishii E, Janka G, Jordan MB, La Rosée P, Lehmberg K, Machowicz R, Nichols KE, Sieni E, Wang Z, Henter JI. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1508-1517. doi: 10.1016/j.jaip.2018.05.031. Epub 2018 Jul 4. Review. — View Citation
Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31. — View Citation
Tang Y, Xu X, Song H, Yang S, Shi S, Wei J, Pan B, Zhao F, Liao C, Luo C. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol. 2008 Oct;143(1):84-91. doi: 10.1111/j.1365-2141.2008.07298.x. Epub 2008 Jul 31. — View Citation
Wang J, Zhang R, Wu X, Li F, Yang H, Liu L, Guo H, Zhang X, Mai H, Li H, Wang Z. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial. Br J Haematol. 2021 May;193(4):761-768. doi: 10.1111/bjh.17331. Epub 2021 Feb 9. — View Citation
Xu XJ, Luo ZB, Song H, Xu WQ, Henter JI, Zhao N, Wu MH, Tang YM. Simple Evaluation of Clinical Situation and Subtypes of Pediatric Hemophagocytic Lymphohistiocytosis by Cytokine Patterns. Front Immunol. 2022 Feb 28;13:850443. doi: 10.3389/fimmu.2022.850443. eCollection 2022. — View Citation
Xu XJ, Tang YM, Song H, Yang SL, Xu WQ, Zhao N, Shi SW, Shen HP, Mao JQ, Zhang LY, Pan BH. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012 Jun;160(6):984-90.e1. doi: 10.1016/j.jpeds.2011.11.046. Epub 2012 Jan 9. — View Citation
Xu XJ, Tang YM. Dilemmas in diagnosis and management of hemophagocytic lymphohistiocytosis in children. World J Pediatr. 2020 Aug;16(4):333-340. doi: 10.1007/s12519-019-00299-3. Epub 2019 Sep 10. Review. — View Citation
Zhang Q, Zhao YZ, Ma HH, Wang D, Cui L, Li WJ, Wei A, Wang CJ, Wang TY, Li ZG, Zhang R. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis. Blood. 2022 Jun 16;139(24):3493-3504. doi: 10.1182/blood.2021014860. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete remission (CR) | Complete remission rate in 8th week | 8th week after the initial of therapy | |
Primary | Overall survival (OS) | Overall survival rate in one year | One year after enrollment | |
Primary | overall response rate (ORR) | including the proportion of patients achieving CR, PR and HLH improvement | At the 4th and 8th week of treatment | |
Primary | Mortality | 8-week mortality | At the 8th week of diagnosis | |
Secondary | Reactivation rate | The relapse rate of disease | Any time during the first year after diagnosis | |
Secondary | Partial remission (PR) | Partial remission rate in 4th week | 4th week after the initial of therapy | |
Secondary | Rate of Early Death | Death occurred within 2 weeks after diagnosis | 2nd week after diagnosis |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03685383 -
Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation
|
N/A | |
Completed |
NCT05307601 -
Immune Response Following COVID-19 in Hemodialysis Patients
|
||
Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT04476745 -
The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People
|
N/A | |
Completed |
NCT04798677 -
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
|
N/A | |
Completed |
NCT01302223 -
Keratinocyte Growth Factor and Cytokines in Burns.
|
N/A | |
Completed |
NCT04483271 -
The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm
|
N/A | |
Not yet recruiting |
NCT05013034 -
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
|
Phase 2 | |
Completed |
NCT04910893 -
Cytokine Adsorption in Severe, Refractory Septic Shock
|
N/A | |
Completed |
NCT04854252 -
Inflammatory Response to Opioid Versus Opioid Free Anesthesia
|
N/A | |
Completed |
NCT04366908 -
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
|
Phase 2 | |
Terminated |
NCT04415073 -
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
|
Phase 2 | |
Completed |
NCT04377308 -
Fluoxetine to Reduce Intubation and Death After COVID19 Infection
|
Phase 4 | |
Completed |
NCT04324528 -
Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT05476848 -
Relationship Between Oral Findings and Salivary Factors in Sars-Cov-2 Patients
|
N/A | |
Completed |
NCT04913298 -
Prospective Study for the Application of Cytosorb® in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04753476 -
Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia
|
Phase 2 | |
Terminated |
NCT04327505 -
Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04433078 -
RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM
|
Phase 2 | |
Completed |
NCT04901338 -
Cytokine Hemoadsorption in ECMO Patients
|